DBS for Epilepsy: Difference between revisions
Jump to navigation
Jump to search
(Created page with "= SANTE TRIAL = ANT DBS for Epilepsy * First RCT - FDA approval in April 2018 * Sponsored by Medtronic * 157 patients enrolled, 110 implanted (2003-2007, 17 US centers) * Age 18-65 * Active 5V, cycling mode) vs. no stimulation during blinding (3 months) * 40.4% reduction in sz (active) vs. 14.5% reduction (control) (p=0.0017) * Side effects: paresthesia, memory decline, dizziness, implant site pain * Complications: infections (10/110) Category:Functional Neurosurgery...") |
No edit summary |
||
| Line 12: | Line 12: | ||
[[Category:Functional Neurosurgery]] | [[Category:Functional Neurosurgery]] | ||
[[Category:Epilepsy]] | [[Category:Epilepsy]] | ||
[[Category:DBS]] | |||
Latest revision as of 10:33, 26 July 2024
SANTE TRIAL
ANT DBS for Epilepsy
- First RCT - FDA approval in April 2018
- Sponsored by Medtronic
- 157 patients enrolled, 110 implanted (2003-2007, 17 US centers)
- Age 18-65
- Active 5V, cycling mode) vs. no stimulation during blinding (3 months)
- 40.4% reduction in sz (active) vs. 14.5% reduction (control) (p=0.0017)
- Side effects: paresthesia, memory decline, dizziness, implant site pain
- Complications: infections (10/110)